[Ophthalmological use of bencyclane and ophthalmodynamometric recording of its effect on cerebral vessels].
D000368:Aged; D001161:Arteriosclerosis / Q000188:drug therapy; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D002561:Cerebrovascular Disorders / Q000188:drug therapy; D003508:Cycloheptanes / Q000494:pharmacology / Q000627:therapeutic use*; D005128:Eye Diseases / Q000188:drug therapy*; D005260:Female; D005650:Fumarates / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009443:Neuritis / Q000188:drug therapy; D009884:Ophthalmodynamometry; D010208:Papaverine / Q000627:therapeutic use; D010276:Parasympatholytics / Q000494:pharmacology / Q000627:therapeutic use*; D011437:Propylamines / Q000494:pharmacology / Q000627:therapeutic use*; D014652:Vascular Diseases / Q000188:drug therapy*; D014665:Vasodilator Agents / Q000627:therapeutic use
D003508:Cycloheptanes; D005650:Fumarates; D010276:Parasympatholytics; D011437:Propylamines; D014665:Vasodilator Agents; D010208:Papaverine
Die ophthalmologische Anwendung von Bencyclan ud die ophthalmodynamometrische Registrierung und seine Wirkung auf die Gefässe des Gehirns.